Article
Oncology
Corinna Haist, Zoe Poschinski, Arthur Bister, Michele J. Hoffmann, Camilla M. Grunewald, Alexandra Hamacher, Matthias Kassack, Constanze Wiek, Kathrin Scheckenbach, Helmut Hanenberg
Summary: The study successfully generated a high-affinity EGFR CAR construct and demonstrated its efficacy and specificity in combating head and neck squamous cell carcinoma and other solid cancers.
Article
Oncology
Hikmat H. Assi, Chihunt Wong, Kimberly A. Tipton, Li Mei, Ken Wong, Jennifer Razo, Chanty Chan, Bruce Howng, Jason Sagert, Michael Krimm, Linnea Diep, Andrew Jang, Margaret T. Nguyen, Nicole Lapuyade, Victoria Singson, Ruth Villanueva, Madan Paidhungat, Shouchun Liu, Vangipuram Rangan, Olga Vasiljeva, James W. West, Jennifer H. Richardson, Bryan Irving, Dylan Daniel, Marcia Belvin, W. Michael Kavanaugh
Summary: Using protease-activatable antibody prodrugs (Pb-Tx) to locally inhibit PD-1/PD-L1 can reduce systemic immune toxicity while eliciting potent anti-tumor immune responses.
CANCER IMMUNOLOGY RESEARCH
(2021)
Article
Oncology
Prachi Bhave, Tasnia Ahmed, Serigne N. Lo, Alexander Shoushtari, Anne Zaremba, Judith M. Versluis, Joanna Mangana, Michael Weichenthal, Lu Si, Thierry Lesimple, Caroline Robert, Claudia Trojanello, Alexandre Wicky, Richard Heywood, Lena Tran, Kathleen Batty, Florentia Dimitriou, Anna Stansfeld, Clara Allayous, Julia K. Schwarze, Meghan J. Mooradian, Oliver Klein, Inderjit Mehmi, Rachel Roberts-Thomson, Andrea Maurichi, Hui-Ling Yeoh, Adnan Khattak, Lisa Zimmer, Christian U. Blank, Egle Ramelyte, Katharina C. Kaehler, Severine Roy, Paolo A. Ascierto, Olivier Michielin, Paul C. Lorigan, Douglas B. Johnson, Ruth Plummer, Celeste Lebbe, Bart Neyns, Ryan Sullivan, Omid Hamid, Mario Santinami, Grant A. McArthur, Andrew M. Haydon, Georgina Long, Alexander M. Menzies, Matteo S. Carlino
Summary: Acral melanoma is a rare subtype with poor prognosis, and there is a lack of prospective clinical trial evidence on the efficacy of checkpoint inhibitors in this population. The study found that initial anti-PD-1/ipilimumab combination had a significantly higher ORR compared to anti-PD-1 alone, but this benefit did not translate to improved OS in this retrospective cohort. Primary site did not impact treatment outcomes.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2022)
Article
Oncology
Krzysztof Piersiala, Pedro Farrajota Neves da Silva, Vilma Lagebro, Aeneas Kolev, Magnus Starkhammar, Alexandra Elliot, Linda Marklund, Eva Munck-Wikland, Gregori Margolin, Susanna Kumlien Georen, Lars-Olaf Cardell
Summary: This study found a high infiltration of Tregs expressing high levels of CTLA-4 and PD-1 in tumour draining lymph nodes (TDLNs) and metastatic lymph nodes (LNs). The high accumulation of these Tregs in TDLNs and LNs may contribute to an immunosuppressive environment that favors cancer progression. The expression of these immune checkpoint molecules is associated with lymph node involvement but not with the size of the primary tumour.
TRANSLATIONAL ONCOLOGY
(2022)
Article
Immunology
B. Leticia Rodriguez, Limo Chen, Yanli Li, Shucheng Miao, David H. Peng, Jared J. Fradette, Lixia Diao, Jessica M. Konen, Frank R. Rojas Alvarez, Luisa M. Solis, Xiaohui Yi, Aparna Padhye, Laura A. Gibson, Joshua K. Ochieng, Xiaofei Zhou, Jing Wang, Don L. Gibbons
Summary: The resistance to immune checkpoint blockade (ICB) therapy in non-small cell lung cancer (NSCLC) is associated with infiltrating monocytes, and controlling the differentiation process of monocytes can enhance the therapeutic potential of ICB.
FRONTIERS IN IMMUNOLOGY
(2023)
Article
Oncology
Yasuhiro Nakamura, Kenjiro Namikawa, Yukiko Kiniwa, Hiroshi Kato, Osamu Yamasaki, Shusuke Yoshikawa, Takeo Maekawa, Shigeto Matsushita, Tatsuya Takenouchi, Takashi Inozume, Yasuo Nakai, Satoshi Fukushima, Shintaro Saito, Atsushi Otsuka, Noriki Fujimoto, Taiki Isei, Natsuki Baba, Taisuke Matsuya, Ryo Tanaka, Takahide Kaneko, Masazumi Onishi, Yutaka Kuwatsuka, Kotaro Nagase, Takehiro Onuma, Motoo Nomura, Yoshiyasu Umeda, Naoya Yamazaki
Summary: This study compared the efficacy of PD-1 and PD-1+CTLA-4 for the treatment of advanced AM in Japanese patients. The results showed no significant differences in ORR, PFS, and OS between the two groups in PSM patients. In NAM patients, the PD-1+CTLA-4 group had significantly higher ORR and longer PFS, and PD-1+CTLA-4 was identified as an independent predictor of favorable PFS in NAM patients.
EUROPEAN JOURNAL OF CANCER
(2022)
Article
Oncology
Rachel E. Sanborn, Omid Hamid, Elisabeth Ge de Vries, Patrick A. Ott, Javier Garcia-Corbacho, Valentina Boni, Johanna Bendell, Karen A. Autio, Daniel C. Cho, Ruth Plummer, Mark Stroh, Lawrence Lu, Fiona Thistlethwaite
Summary: The phase 1 study of the Probody immune checkpoint inhibitor CX-072 (pacmilimab) in combination with anti-CTLA-4 antibody ipilimumab showed promising results in terms of efficacy and tolerability in patients with advanced solid tumors.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2021)
Article
Oncology
Natasha B. Leighl, Mary W. Redman, Naiyer Rizvi, Fred R. Hirsch, Philip C. Mack, Lawrence H. Schwartz, James L. Wade, William J. Irvin, Sreekanth C. Reddy, Jeffrey Crawford, Jeffrey D. Bradley, Thomas E. Stinchcombe, Suresh S. Ramalingam, Jieling Miao, Katherine Minichiello, Roy S. Herbst, Vassiliki A. Papadimitrakopoulou, Karen Kelly, David R. Gandara
Summary: The study found that the combination of Durvalumab and Tremelimumab had minimal activity in patients with advanced squamous non-small cell lung cancer, especially those who had received prior PD-1 therapy. There were also observed grade ≥ 3 adverse events in a portion of the patients.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2021)
Review
Pharmacology & Pharmacy
Yuqian Feng, Huimin Jin, Kaibo Guo, Yuying Xiang, Yiting Zhang, Wurong Du, Minhe Shen, Shanming Ruan
Summary: The study supports the efficacy of combination therapy with immune checkpoint inhibitors (ICIs) in cancer treatment, especially showing longer PFS in patients with high PD-L1 expression. More high-quality clinical randomized controlled trials are needed in the future to confirm these findings, as the number of included trials was limited.
FRONTIERS IN PHARMACOLOGY
(2021)
Article
Immunology
Pornpimon Yuti, Yupanun Wutti-in, Nunghathai Sawasdee, Katesara Kongkhla, Nattaporn Phanthaphol, Kornkan Choomee, Thaweesak Chieochansin, Aussara Panya, Mutita Junking, Pa-thai Yenchitsomanus, Jatuporn Sujjitjoon
Summary: Adoptive T cell therapy using second-generation anti-CD19 chimeric antigen receptor T cells has shown promising results in the treatment of B-ALL and DLBCL. However, the efficacy in aggressive B cell lymphomas is limited due to poor T cell function caused by the interaction between PD-L1 on BCL cells and PD-1 receptor on T cells. To overcome this, researchers have generated anti-CD19-CAR5-T cells that secrete anti-PD-L1 scFv, which has shown improved antitumor efficiency against CD19+/PD-L1high tumors.
INTERNATIONAL IMMUNOPHARMACOLOGY
(2022)
Review
Oncology
Wenwen Wei, Dong Yang, Xi Chen, Dandan Liang, Liqun Zou, Xudong Zhao
Summary: This review summarizes the characteristics of non-B-cell acute leukemia and the efficacy and challenges of CAR-T cell therapy in treating this type of leukemia.
FRONTIERS IN ONCOLOGY
(2022)
Article
Oncology
Monika Semmrich, Jean-Baptiste Marchand, Laetitia Fend, Matilda Rehn, Christelle Remy, Petra Holmkvist, Nathalie Silvestre, Carolin Svensson, Patricia Kleinpeter, Jules Deforges, Fred Junghus, Kirstie L. Cleary, Mimoza Boden, Linda Martensson, Johann Foloppe, Ingrid Teige, Eric Quemeneur, Bjorn Frendeus
Summary: This study demonstrates a highly effective and safe strategy to target CTLA-4 using a vectorized alpha CTLA-4 with strong Treg-depleting and checkpoint-blocking properties. This approach shows promising results in enhancing anti-tumor immunity.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2022)
Review
Oncology
Morena Fasano, Carminia Maria Della Corte, Giuseppe Viscardi, Raimondo Di Liello, Fernando Paragliola, Francesca Sparano, Maria Lucia Iacovino, Anna Castrichino, Francesca Doria, Antonello Sica, Floriana Morgillo, Giuseppe Colella, Giampaolo Tartaro, Salvatore Cappabianca, Domenico Testa, Gaetano Motta, Fortunato Ciardiello
Summary: Head and neck cancers are the seventh most common cancer worldwide, with squamous cell carcinomas being the most frequent histologic subtype. The current standard treatment includes surgery or radiotherapy for early stage diseases, while locally advanced cases may require a more aggressive multi-modal approach. Anti-EGFR targeted therapy cetuximab is currently the only approved targeted therapy option, with the recent development of immune-checkpoint inhibitors providing new treatment options.
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY
(2021)
Review
Immunology
Peng Zhang, Yang Zhang, Nan Ji
Summary: Glioblastoma (GBM) is a deadly brain cancer with limited efficacy of standard treatments, necessitating the development of new therapies. Chimeric antigen receptor T (CAR-T) cell immunotherapy has shown success in hematological malignancies, but has not yet yielded promising results in GBM. CAR-T cell therapy for GBM faces challenges including tumor heterogeneity, immunosuppressive microenvironment, and cell persistence.
FRONTIERS IN IMMUNOLOGY
(2022)
Review
Oncology
Hao Zhang, Ziyu Dai, Wantao Wu, Zeyu Wang, Nan Zhang, Liyang Zhang, Wen-Jing Zeng, Zhixiong Liu, Quan Cheng
Summary: The regulatory mechanisms of PD-L1 and CTLA-4 play a crucial role in immunotherapy, and understanding their interactions can help improve patients' treatment responses and clinical care.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
(2021)
Article
Biochemistry & Molecular Biology
Kevin Brennan, Hong Zheng, Jill A. Fahrner, June Ho Shin, Andrew J. Gentles, Bradley Schaefer, John B. Sunwoo, Jonathan A. Bernstein, Olivier Gevaert
Summary: By studying the transcription and DNA methylation of Sotos syndrome (SS) patients and healthy controls, it was found that mutations in NSD1 lead to dysregulation of transcription and DNA methylation. The gene expression abnormalities observed in SS resemble those seen in certain cancers. The downregulated genes in SS are mainly involved in development and neural synapse function regulation. Additionally, accelerated molecular aging was observed in the transcription and DNA methylation levels of SS patients.
HUMAN MOLECULAR GENETICS
(2022)
Article
Biochemistry & Molecular Biology
Nathan E. Reticker-Flynn, Weiruo Zhang, Julia A. Belk, Pamela A. Basto, Nichole K. Escalante, Genay O. W. Pilarowski, Alborz Bejnood, Maria M. Martins, Justin A. Kenkel, Ian L. Linde, Sreya Bagchi, Robert Yuan, Serena Chang, Matthew H. Spitzer, Yaron Carmi, Jiahan Cheng, Lorna L. Tolentino, Okmi Choi, Nancy Wu, Christina S. Kong, Andrew J. Gentles, John B. Sunwoo, Ansuman T. Satpathy, Sylvia K. Plevritis, Edgar G. Engleman
Summary: Lymph node metastasis plays an active role in shaping distant metastasis in solid malignancies, and this mechanism involves the evasion of immune cells, colonization in lymph nodes, and subsequent colonization in other tissues. This mechanism is conserved in human cancers and murine cancer models.
Article
Biochemical Research Methods
Weiruo Zhang, Irene Li, Nathan E. Reticker-Flynn, Zinaida Good, Serena Chang, Nikolay Samusik, Saumyaa Saumyaa, Yuanyuan Li, Xin Zhou, Rachel Liang, Christina S. Kong, Quynh-Thu Le, Andrew J. Gentles, John B. Sunwoo, Garry P. Nolan, Edgar G. Engleman, Sylvia K. Plevritis
Summary: CELESTA is an unsupervised machine learning algorithm that identifies cell types based on markers and spatial information. By applying CELESTA to imaging data of colorectal cancer and head and neck squamous cell carcinoma, researchers identified tissue architecture associated with lymph node metastasis and validated their findings through cell-cell interaction analysis.
Article
Oncology
Li Guan, Dhanya K. Nambiar, Hongbin Cao, Vignesh Viswanathan, Shirley Kwok, Angela B. Hui, Yuan Hou, Rachel Hildebrand, Rie von Eyben, Brittany J. Holmes, Junfei Zhao, Christina S. Kong, Nathan Wamsley, Weiruo Zhang, Michael B. Major, Seung W. Seol, John B. Sunwoo, D. Neil Hayes, Maximilian Diehn, Quynh-Thu Le
Summary: Radiotherapy is a primary treatment for head and neck squamous cell carcinoma (HNSCC), but there is currently no reliable biomarker for predicting radioresistance. This study found that mutations in the NFE2L2 gene are associated with higher rates of locoregional failure in HNSCC patients treated with surgery and (chemo)radiotherapy. NFE2L2 mutations lead to radioresistance through Nrf2 activation, but this can be overcome by the glutaminase inhibitor CB-839.
Article
Oncology
Chen Chen, June Ho Shin, Zhuoqing Fang, Kevin Brennan, Nina B. Horowitz, Kathleen L. Pfaff, Emma L. Welsh, Scott J. Rodig, Olivier Gevaert, Or Gozani, Ravindra Uppaluri, John B. Sunwoo
Summary: In head and neck squamous cell carcinoma (HNSCC), inactivating mutations in the histone methyltransferase NSD1 disproportionately contribute to tumor development and immune exclusion. Understanding the NSD1-mediated mechanism and targeting the histone-modifying enzyme KDM2A could enhance T-cell infiltration and suppress tumor growth in HNSCC.
Review
Immunology
Jakob Einhaus, Xiaoyuan Han, Dorien Feyaerts, John Sunwoo, Brice Gaudilliere, Somayeh H. Ahmad, Nima Aghaeepour, Karl Bruckman, David Ojcius, Christian M. Schuerch, Dyani K. Gaudilliere
Summary: Oral mucosal pathologies are prevalent diseases worldwide and have medical significance. They can cause disfigurement and greatly reduce quality of life in a confined space with important physiological and social functions. However, treatment for these diseases is often ineffective and there is limited research on them. The host's immune system plays a major role in the development, maintenance, and resolution of oral mucosal pathologies, making a precise understanding of immunological mechanisms crucial for accurate diagnosis, targeted immunotherapy, and personalized treatment. This review highlights recent advancements in multiomic and single-cell approaches that provide comprehensive insights and clinically relevant biological signatures for these pathophysiological processes.
SEMINARS IN IMMUNOPATHOLOGY
(2023)
Review
Oncology
Quan Tran, Sainiteesh Maddineni, Ethan Hunter Arnaud, Vasu Divi, Uchechukwu C. Megwalu, Michael C. Topf, John B. Sunwoo
Summary: Oral squamous cell carcinoma (OSCC) in non-smoking and non-drinking individuals is different from traditional head and neck squamous cell carcinoma (HNSCC). The incidence of this type of cancer is increasing, especially in young females, and the tongue is the most affected subsite. Although gene mutations and unique epigenomic profiles have been identified, there is no definitive genetic cause. Other possible causes include chronic dental trauma, microbiome abnormalities, marijuana consumption, and genetic disorders.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
(2023)
Article
Medicine, Research & Experimental
Alice E. Huang, Jonathan J. J. Shih, John B. B. Sunwoo, Erqi Pollom, Kekoa Taparra
Summary: This study investigates the readmission rate after head and neck surgery within 30 days among different racial groups, and finds that Native Hawaiians and other Pacific Islanders (NHPI) patients have higher readmission rates compared to Asian individuals. This highlights the importance of racial disaggregation in clinical studies.
Article
Cell Biology
Nupur Nigam, Benjamin Bernard, Samantha Sevilla, Sohyoung Kim, Mohd Saleem Dar, Daniel Tsai, Yvette Robbins, Kyunghee Burkitt, Cem Sievers, Clint T. Allen, Richard L. Bennett, Theophilus T. Tettey, Benjamin Carter, Lorenzo Rinaldi, Mark W. Lingen, Houssein Sater, Elijah F. Edmondson, Arfa Moshiri, Abbas Saeed, Hui Cheng, Xiaolin Luo, Kevin Brennan, Vishal Koparde, Chen Chen, Sudipto Das, Thorkell Andresson, Abdalla Abdelmaksoud, Madhavi Murali, Seiji Sakata, Kengo Takeuchi, Raj Chari, Yusuke Nakamura, Ravindra Uppaluri, John B. Sunwoo, Carter Van Waes, Jonathan D. Licht, Gordon L. Hager, Vassiliki Saloura
Summary: We identified SMYD3 as a mediator of immune escape in HPV-negative HNSCC. SMYD3 depletion upregulates type I IFN response and antigen presentation genes in HNSCC cells. Mechanistically, SMYD3 regulates the transcription of UHRF1, which binds to H3K9me3-enriched promoters of immune-related genes and silences their expression.
Review
Oncology
Sainiteesh Maddineni, Michelle Chen, Fred Baik, Vasu Divi, John B. Sunwoo, Andrey Finegersh
Summary: A meta-analysis of existing clinical trials for recurrent and metastatic head and neck cancer found that Toll-like receptor agonists do not provide additional clinical benefits and do not increase adverse events in the treatment of this cancer. Future clinical trials may need to focus on new agents or drug combinations.
Article
Multidisciplinary Sciences
Eric Wu, Alexandro E. Trevino, Zhenqin Wu, Kyle Swanson, Honesty J. Kim, H. Blaize D'Angio, Ryan Preska, Aaron E. Chiou, Gregory W. Charville, Piero Dalerba, Umamaheswar Duvvuri, Alexander D. Colevas, Jelena Levi, Nikita Bedi, Serena Chang, John Sunwoo, Ann Marie Egloff, Ravindra Uppaluri, Aaron T. Mayer, James Zou
Summary: Researchers propose a machine learning framework called 7-UP that can computationally generate 40-plex CODEX from a standard 7-plex mIF panel by leveraging cellular morphology. They demonstrate the usefulness of the imputed biomarkers in accurately classifying cell types and predicting patient survival outcomes. The imputations of 7-UP generalize well across samples from different clinical sites and cancer types.
Meeting Abstract
Dermatology
V. Muralidharan, S. Maddineni, L. Young, J. Sunwoo, F. M. Baik, S. Swetter
JOURNAL OF INVESTIGATIVE DERMATOLOGY
(2023)
Article
Genetics & Heredity
Kevin Brennan, Almudena Espin-Perez, Serena Chang, Nikita Bedi, Saumyaa Saumyaa, June Ho Shin, Sylvia K. Plevritis, Olivier Gevaert, John B. Sunwoo, Andrew J. Gentles
Summary: In this study, we conducted a large-scale analysis of transcriptomic data to identify molecular pathways that drive metastasis and progression in head and neck cancer (HNC). Our findings suggest that patient survival is influenced by multiple biological processes and the tumor immune and stromal microenvironments, while lymph node metastasis (LNM) is primarily driven by malignant cell plasticity characterized by epithelial dedifferentiation, independent of epithelial-mesenchymal transition (EMT).
Meeting Abstract
Oncology
Diane Simeone, Maria Pia Morelli, J. Randolph Hecht, Sandip Patel, Marwan Fakih, Kedar Kirtane, Theodore Welling, Sally Lau, Yi Lin, Mitesh Borad, Edward Garon, Sarah Larson, Shumei Kato, Peter Vu, Frederick Locke, Dae Won Kim, John Sunwoo, David Miklos, Matthew Frigault, Marcela Maus, Sarah Nikiforow, Caron Jacobson, Kirstin Liechty, Armen Mardiros, Ariane Lozac'hmeur, Karl Beutner, John Welch, Eric Ng, William Go, David Maloney, Scott Kopetz, Julian Molina
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2022)
Meeting Abstract
Oncology
Diane M. Simeone, J. Randolph Hecht, Sandip Pravin Patel, Maria Pia Morelli, Kedar Kirtane, Mitesh J. Borad, Marcela Valderrama Maus, John B. Sunwoo, Theodore Welling, Yi Lin, Edward B. Garon, Scott Kopetz, Frederick L. Locke, Kirstin B. Liechty, Ariane Lozac'hmeur, Karl Beutner, Eric Wai-Choi Ng, William Y. Go, David G. Maloney, Julian R. Molina
JOURNAL OF CLINICAL ONCOLOGY
(2022)
Article
Oncology
Toma S. Omofoye, Anganile Kalinga, Ramapriya Ganti, Frank J. Minja, Timothy B. Rooney
HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA
(2024)
Article
Oncology
Prarthna V. Bhardwaj, Renuka Dulala, Senthil Rajappa, Chandravathi Loke
Summary: The management of breast cancers in India needs greater emphasis on awareness, early detection, standard pathologic testing, and cost-effective solutions. With standardized management, outcomes similar to those of developed countries can be expected. Additionally, clinical trials aimed at a more diverse population in LMICs like India should be undertaken.
HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA
(2024)
Article
Oncology
Victoria E. Forbes, Mary D. Chamberlin, Vincent Dusabejambo, Tim Walker, Steve P. Bensen, Norrisa Haynes, Kathryn Nunes, Veauthyelau Saint-Joy, Frederick L. Makrauer
Summary: Global health education needs to adapt to the challenges we face, such as inequities and pandemics. Virtual teaching models are effective in delivering global health education and improving outcomes through bidirectional learning and equitable partnerships.
HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA
(2024)
Article
Oncology
Tefta Isufaj Haliti, Ilir Hoxha, Rubena Mojsiu, Rohini Mandal, Goksu Goc, Kreshnike Dedushi Hoti
Summary: The IOTA Simple Rules have high diagnostic performance in distinguishing between benign and malignant adnexal masses, providing a reliable tool for early diagnosis of ovarian cancer.
HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA
(2024)
Article
Oncology
Cecilia Felix Penido Mendes de Sousa, Jared Pasetsky, Gustavo Nader Marta, Megan Kassick, Fabio Ynoe Moraes, Luqman K. Dad
HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA
(2024)
Article
Oncology
Mary D. Chamberlin, Dafina Ademi Islami, Shqiptar Demaci, Richard J. Barth Jr
HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA
(2024)
Review
Oncology
Jeta Bunjaku, Arber Lama, Tawanda Pesanayi, Jeton Shatri, Mary Chamberlin, Ilir Hoxha
Summary: The evidence suggests that lifestyle factors such as alcohol and coffee intake may increase the risk of lung cancer, while tea intake may have a protective effect. However, the quality of evidence is currently low and further research is needed.
HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA
(2024)
Article
Oncology
Mary Chamberlin, Christopher Booth, Gabriel A. Brooks, Achille Manirakiza, Fidel Rubagumya, Verna Vanderpuye
HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA
(2024)
Article
Oncology
Anne Christine Buteau, Alicia Castelo-Loureiro, Regina Barragan-Carrillo, Suyapa Bejarano, Alba J. Kihn-Alarcon, Enrique Soto-Perez-de-Celis
HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA
(2024)
Review
Oncology
Ilir Hoxha, Fitim Sadiku, Lot Hoxha, Midhet Nasim, Marie Anne Christine Buteau, Krenare Grezda, Mary D. Chamberlin
HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA
(2024)
